Cellectis Presents Promising Gene Therapy and TALE Base Editor Data at ESGCT Annual Congress

Cellectis will present data on non-viral gene therapy and TALE base editors at the ESGCT annual congress. The company's research highlights the potential of circular single-stranded DNA as a universal, efficient non-viral template for gene therapy, and a comprehensive study of TALE base editors' off-target effects in the nuclear genome. The findings demonstrate high gene insertion frequency and viability in hematopoietic stem and progenitor cells, as well as a higher propensity to engraft and maintain gene edits compared to adeno-associated viruses.